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This study examines the effect of changes in the vintage distribution of cardiovascular system drugs
on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data.
The vintage of a drug is the first year in which it was marketed anywhere in the world. We use annual
data on the utilization of over 1100 cardiovascular drugs (active ingredients) in 20 OECD countries
during the period 1995-2003. 
Countries with larger increases in the share of cardiovascular drug doses that contained post-1990
or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate,
controlling for the quantity of cardiovascular medications consumed per person, the use of other medical
innovations (CT scanners & MRI units), potential risk factors (average consumption of calories, tobacco,
and alcohol), and demographic variables (population size & age structure, income, and educational
attainment). The estimates also indicate that use of newer cardiovascular drugs has reduced average
length of stay and the age-adjusted cardiovascular mortality rate, but not the number of potential years
of life lost due to cardiovascular disease before age 70 per 100,000 population. 
The estimates indicate that if drug vintage had not increased during 1995-2004, hospitalization and
mortality would have been higher in 2004. We estimate that per capita expenditure on cardiovascular
hospital stays would have been 70% ($89) higher in 2004 had drug vintage not increased during 1995-2004.
Per capita expenditure on cardiovascular drugs would have been lower in 2004 had drug vintage not
increased during 1995-2004. But our estimate of the increase in expenditure on cardiovascular hospital
stays is about 3.7 times as large as our estimate of the reduction in per capita expenditure for cardiovascular
drugs that would have occurred ($24).
Frank R. Lichtenberg
Graduate School of Business
Columbia University
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New York, NY  10027
and NBER
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New drugs tend to be more expensive than old drugs.  Many people might 
therefore expect greater use of new drugs to increase total medical expenditure.  This is 
not necessarily the case, however.  If new drugs are more effective than older drugs, use 
of newer drugs might reduce other medical (e.g. hospital) expenditure more than it 
increases drug expenditure.   
A number of previous studies have investigated the hypothesis that use of newer 
drugs has reduced other medical expenditure.  Some of these studies have investigated 
whether new drugs in general—i.e., drugs in all therapeutic classes and for all diseases—
have reduced other medical expenditure.  These studies have used a variety of 
methodologies and kinds of data.  Lichtenberg (2001) examined condition-by-patient-
level data from the 1996 Medical Expenditure Panel Survey.  Lichtenberg (2006a) 
examined longitudinal state-level data from the period 1997-2003, and Lichtenberg 
(2007a) examined longitudinal disease-level data from the period 1990-2003.  All three 
of these studies, which were based on U.S. data, provided support for the hypothesis that, 
overall, using newer drugs has reduced other types of medical expenditure, particularly 
hospital expenditure. 
Other studies have examined specific classes of drugs.  Miller et al (2005) 
investigated whether use of newer cardiovascular drugs reduced other medical 
expenditure.  They concluded that there was no relationship between use of newer drugs 
and non-drug expenditure.  However Lichtenberg (2006b) argued that their analysis had 
some serious flaws, and that their conclusions should be viewed with considerable 
skepticism.  In particular, they controlled for factors that should not have been controlled 
for, and they controlled poorly for factors that should have been controlled for. 
Weisfeldt and Zieman (2007) surveyed evidence from clinical trials about drug 
and device efficacy in the prevention and treatment of coronary artery disease and heart 
failure during the period 1970-2010.  They concluded that pharmaceutical agents played 
a major role in prevention of atheroscierosis and its consequences (heart attack, stroke, 
and heart failure), and that the marked reduction in cardiovascular disease and its 
consequences was largely driven by the development and implementation of drugs for 
long-term use and by complicated and costly procedures and operations for acute disease 
management.  Two other lessons that emerged from their survey of the clinical literature   4
are worth noting here.  First, the introduction of new drugs within a class may improve 
the health of the population, even if newer agents do not strictly dominate older agents 
(i.e., they are not superior for every patient), because not all members of the population 
benefit similarly from the use of specific agents in a particular drug class.
1  Second, 
evidence from clinical trials showing the efficacy of a drug may first be published many 
years after the class was launched.  For example, according to Weisfeldt and Zieman, 
evidence from clinical trials showing the efficacy of aldosterone antagonists for 
preventing and treating coronary heart disease was first published in 1999, 39 years after 
the first drug in the class (spironolactone) was approved by the FDA.
2   
This study will examine the effect of changes in the vintage distribution of 
cardiovascular system drugs on hospitalization and mortality due to cardiovascular 
disease using longitudinal country-level data.  The vintage of a drug is defined as the year 
in which the drug was first sold anywhere in the world.  The concept of vintage has 
hardly been used in health economics, but it is well established in both theoretical and 
empirical analysis in other areas of economics.
3   
We will use annual data on the utilization of over 1100 cardiovascular drugs 
(active ingredients) in 20 OECD countries during the period 1995-2004.  Cardiovascular 
drugs comprise the largest therapeutic class of drugs, in terms of expenditure, in 13 key 
global markets IMS Health (2006).  Heart disease was the most frequent cause of 
hospitalization in the U.S. in 1999 (Popovic and Hall (2001)).   
  Section I of this paper describes the econometric models that we will estimate.  
Data sources and descriptive statistics are discussed in Section II.  Empirical results are 
                                                 
1 Thus, the introduction of new statins might have benefited patients even though Zhou et al (2006) 
concluded from published statin randomized placebo-controlled trials that pravastatin, simvastatin, and 
atorvastatin, when used at their standard dosages, showed no statistically significant difference in their 
effect on long-term cardiovascular prevention. Moreover Cannon et al (2004) found that patients taking 80 
milligrams of atorvastatin (launched in January 1997) were 16% less likely to die, have a heart attack, 
undergo bypass or angioplasty surgery, or develop worsening chest pain than those taking 40 milligrams of 
pravastatin (launched in October 1989).   
2 The class includes just one other drug: eplerenone, which was approved by the FDA in 2002. 
3 See Boucekkine et al (2006) for a brief survey of the theoretical literature on vintage capital.  Empirical 
studies by Hulten (1992), Bahk and Gort (1993), and Sakellaris and Wilson (2004) have demonstrated that 
the vintage of capital equipment has an important effect on productivity in manufacturing.   5
presented in Section III.  Implications of the estimates are considered in Section IV.  The 
final section presents a summary. 
 
I.  Methodology 
 
We will estimate models of the following form, using longitudinal country-level 
data: 
ln Yit = β rx_vintit + γ Zit + αi + δt + εit   (1) 
where  
Yit  = a measure of hospital use or mortality due to cardiovascular disease in 
country i (i = 1,…,21) in year t (t = 1995,…,2003) 
rx_vintit  = a measure of the vintage distribution of cardiovascular system (ATC class C) 
drugs used in country i in year t 
Zit  = other potential determinants of hospital use or mortality due to 
cardiovascular disease in country i in year t 
αi  = a fixed effect for country i 
δt  = a fixed effect for year t 
 
Since the model includes country and year fixed effects, it is a difference-in-differences 
model.  Negative and significant estimates of β would indicate that, ceteris paribus, 
countries with above-average increases in cardiovascular drug vintage had above-average 
declines (or below-average increases) in cardiovascular hospital use and mortality. 
  This model is static: it is predicated on the assumption that hospital use and 
mortality depend on contemporaneous values of drug vintage and other variables.  In 
reality, health outcomes might depend on lagged as well as contemporaneous values of 
the explanatory variables.
4  But there are two practical reasons to estimate a static model.  
First, the time-series is relatively short, since 1995 is the first year for which the drug data 
are available.  Including lagged vintage would therefore significantly reduce the number 
of sample observations.  Second, many of the explanatory variables exhibit high serial 
correlation.  This makes precise identification of the lag structure challenging, and would 
cause multicollinearity if lagged as well as current values of regressors were included. 
                                                 
4 Weisfeldt and Zieman (2007) observe that, unlike therapies used in infectious diseases, cardiovascular 
agents offer no rapid "cure." Rather, they prevent or reduce the progression of disease when ingested 
continuously.   6
Dependent variables 
 
We will estimate models of the following measures of hospital use or mortality due to 
cardiovascular disease: 
•  The number of hospital discharges
5 in which the principal diagnosis was 
cardiovascular disease per 100,000 population (n_discharges) 
•  Average length of stay
6 in hospital discharges in which the principal diagnosis 
was cardiovascular disease (alos) 
•  The number of hospital days in which the principal diagnosis was cardiovascular 
disease per 100,000 population (n_days = n_discharges * alos) 
•  The (age-standardized) number of deaths caused by diseases of the circulatory 
system
7 per 100,000 population (n_deaths) 




Measures of the vintage distribution of cardiovascular system drugs 
 
We will use two different measures of the vintage distribution of cardiovascular 
system drugs.  Both are based on the following general definition of drug vintage: 
 




n_unitsdit  = the number of standard units
9 of cardiovascular drug d sold in country i 
in year t 
                                                 
5 Discharge is the formal release of an in-patient from an acute care institution after a period of 
"hospitalization". It includes deaths in hospitals, but excludes same-day separations and transfers to other 
care units within the same institution. However, the following countries include at least some same-day 
separations: Austria, Czech Republic, France, Hungary, New Zealand and the United States. 
6 Average length of stay (ALOS) is calculated by dividing the number of days stayed (from the date of 
admission in an in-patient institution) by the number of discharges (including deaths). 
7 The age-standardized number of deaths is calculated as the population times the age-standardized death 
rate. The latter is calculated by the OECD Secretariat, using the total OECD population for 1980 as the 
reference population. The age-standardized death rates are necessary for comparing the level of mortality 
across countries and over time since they take into account the differences in age structure of the 
populations.  
8 Potential years of life lost (PYLL) is a summary measure of premature mortality which provides an 
explicit way of weighting deaths occurring at younger ages, which are, a priori, preventable. The 
calculation of PYLL involves summing up deaths occurring at each age and multiplying this with the 
number of remaining years to live up to a selected age limit.   The limit of 70 years has been chosen for the 
calculations in OECD Health Data.  In order to assure cross- country and trend comparison, the PYLL are 
standardized for each country i and each year t. 
9 A standard unit is equivalent to a standard dose of medication (Aldonas (2005)).  Standard Units (SU) are 
determined by taking the number of counting units (e.g. actual number of ml in a bottle) and dividing it by   7
launch_yeard  = the year of initial world launch of cardiovascular drug d 
 
The two measures are based on two different forms of the function f(launch_yeard): 
 
f1(launch_yeard)  = 1 if launch_yeard > 1995 
  = 0 if launch_yeard < 1995 
  
f2(launch_yeard)  = 1 if launch_yeard > 1990 
  = 0 if launch_yeard < 1990 
  
The two corresponding measures of cardiovascular drug vintage are: 
 
rx_post1995%it   = Σd n_unitsdit f1(launch_yeard) / Σd n_unitsdit 
= the fraction of standard units whose active ingredients 
were launched after 1995 
 
rx_post1990%it   = Σd n_unitsdit f2(launch_yeard) / Σd n_unitsdit 
= the fraction of standard units whose active ingredients 
were launched after 1990 
 
Other potential determinants of hospital use or mortality due to cardiovascular disease 
 
  In addition to cardiovascular drug vintage, the models of cardiovascular 
hospitalization and mortality we estimate will include several other types of explanatory 
variables: the quantity of cardiovascular medications consumed per person; indicators of 
the use of other medical innovations (CT scanners & MRI units); indicators of potentially 
important cardiovascular risk factor (calories consumed per person per day and per capita 
expenditure on tobacco and alcohol); and demographic variables (population size & age 
structure, income, and educational attainment).  In particular, the models will include the 
following covariates: 
 
ln(n_cv_suit)  = the log of the number of standard units of cardiovascular drugs 
per person 
ln(ct_scanit)  = the log of the number of computed tomography scanners per 
million population 
ln(mriit)  = the log of the number of magnetic resonance imaging units per 
million population 
                                                                                                                                                 
the smallest common dose of a product as defined by IMS Health.  For example, oral solids have an SU of 
one tablet or capsule, whereas for syrup forms it is 5ml and for injectable forms it is one ampoule or vial.   8
ln(caloriesit)  = the log of the average number of calories consumed per person 
per day
10 
ln(tobaccoit)  = the log of per capita expenditure on tobacco (in PPP US dollars) 
ln(alcoholit)  = the log of per capita expenditure on alcohol (in PPP US dollars) 
ln(popit)  = the log of the population  
age_ge_65%it  = the fraction of the population age 65 and over 
ln(gdpit)  = the log of per capita GDP 
edu_low%it  = the fraction of the population with education at or below the 
lower secondary level (ISCED
11 0/1/2) 
edu_mid%it  = the fraction of the population with education at the upper 
secondary or post-secondary, non-tertiary level (ISCED 3/4) 




Cardiovascular disease prevalence.  Ideally, we could control directly for the prevalence 
of cardiovascular disease, i.e. the fraction of the population at risk for cardiovascular 
hospitalization or death.  Unfortunately, reliable data on the prevalence of cardiovascular 
disease, by country and year, are not available.
13  The cardiovascular drug utilization rate 
(n_cv_su) may control, to some extent, for the cardiovascular disease prevalence rate, but 
it also reflects intensity of use among people with the disease: 
 n_cv_su  =   su    ×  prev 
                    prev       pop 
 
An increase in the cardiovascular disease prevalence rate (prev / pop) would increase 
cardiovascular hospitalization and mortality, but an increase in treatment intensity (su / 
prev) might be expected to reduce cardiovascular hospitalization and mortality.  Hence, 
the net effect of an increase in per capita consumption of cardiovascular drugs on 
cardiovascular hospitalization and mortality is theoretically ambiguous.  As indicated 
                                                 
10 The main data source is the Food and Agriculture Organization of the United Nations Nutrition database 
(FAOSTAT).  See http://faostat.fao.org/. 
11 ISCED denotes the International Standard Classification of Education from 1997.  ISCED 5B (programs 
at the tertiary level that focus on practical, technical or occupational skills for direct entry into the labor 
market) is the omitted category. 
12 The omitted education category is the fraction of the population with education at the ISCED 5B level.  
These programs are typically shorter than those of ISCED 5A and focus on practical, technical or 
occupational skills for direct entry into the labor market, although some theoretical foundations may be 
covered in the respective programs. They have a minimum duration of two years full-time equivalent at the 
tertiary level. 
13 HIV/AIDS and cancer are the only chronic diseases for which there are reasonably reliable longitudinal 
estimates of disease prevalence, due to the existence of disease registries.  Lichtenberg (2006c, 2007b) uses 
these data to investigate the effects of pharmaceutical use and innovation on the survival rates of 
HIV/AIDS and cancer patients in the U.S.   9
above, we also control for per capita income and educational attainment, which may 
influence both disease prevalence and the quality of disease management, hence the rate 
of cardiovascular hospitalization and mortality.   
Cardiovascular risk factors.  Instead of, or in addition to, controlling for cardiovascular 
disease prevalence, it is desirable to control for cardiovascular disease risk factors.  
Advanced age, obesity and smoking are known to be cardiovascular disease risk factors.  
Our models of hospital utilization will control for the fraction of the population age 65 
and over.
14  The OECD Health Data 2006 database contains some information about the 
prevalence of obesity and tobacco use.  Unfortunately, the data on these indicators are 
quite incomplete.  For example, data on obesity are available for only 37% (59 out of 
159) of the country-year observations in our sample; data on tobacco use were available 
for 57% (91 out of 159) of the observations.  Including a measure of obesity in the model 
would reduce the number of residual degrees of freedom by 83% (from 111 to 19).  
Therefore the basic models we estimate will not include measures of obesity.  However 
we will control for an important (and frequently reported) determinant of obesity: calories 
consumed per person per day.  We will also control for per capita expenditure (in PPP US 
dollars) on tobacco and on alcohol; data on these variables were obtained from the OECD 
Annual National Accounts database. 
Other medical innovation.  Weisfeldt and Zieman (2007) found that the marked reduction 
in cardiovascular disease and its consequences was largely driven by complicated and 
costly procedures and operations for acute disease management as well as by the 
development and implementation of drugs for long-term use.  It would therefore be ideal 
to control for the rate of adoption of non-pharmaceutical as well as pharmaceutical 
medical innovations relevant to cardiovascular disease.   
The OECD Health Data 2006 database contains five indicators of non-
pharmaceutical medical technology.  Data on all of these indicators are quite incomplete.  
We will control for the use of two medical technologies: CT scanners and MRI units.  
These are the two technologies with the least incomplete data, and that are most relevant 
                                                 
14 Our models of cardiovascular mortality will not control for the fraction of the population age 65 and 
over, because the mortality measures are age-adjusted.   10
to the diagnosis and treatment of cardiovascular disease.
15  Over 73,000 articles in 
MEDLINE refer to both “Cardiovascular Diseases” and either “Tomography, X-Ray 
Computed” or “Magnetic Resonance Imaging”.
16  However CT scanners and MRI units 
are also used to diagnose many other diseases.  These measures may not adequately 
control for non-pharmaceutical cardiovascular disease innovation.   
  If pharmaceutical and non-pharmaceutical cardiovascular disease innovation are 
“complements” (i.e., they are positively correlated across countries), estimates of β could 
be biased away from zero.  On the other hand, if pharmaceutical and non-pharmaceutical 
innovation are “substitutes” (i.e., they are negatively correlated across countries), 
estimates of β could be biased towards zero.  It is not possible to determine the sign of 
the correlation between pharmaceutical and non-pharmaceutical cardiovascular disease 
innovation across countries, but it is possible to determine the sign of this correlation 
across U.S. states.  Using data on the two largest public health insurance programs, we 
constructed the following indicators of the adoption of pharmaceutical and non-
pharmaceutical (i.e. surgical) cardiovascular disease innovations by state in 2004: 
 
rx_post1995%s,2004   = the fraction of Medicaid
17 cardiovascular drug 
prescriptions in state s in 2004 whose active 
ingredients were approved by the FDA after 1995 
rx_post1990%s,2004   = the fraction of Medicaid cardiovascular drug 
prescriptions in state s in 2004 whose active 
ingredients were approved by the FDA after 1990 
surg_post1995%s,2004   = the fraction of Medicare major cardiovascular 
surgical procedures
18 in state s in 2004 with 
procedure codes established by the American 
Medical Association after 1995 
surg_post1990%s,2004   = the fraction of Medicare major cardiovascular 
surgical procedures in state s in 2004 with 
                                                 
15 The other three technologies are radiation therapy equipment, lithotriptors, and mammographs. 
16 See, for example, Harrigan et al (2008) and Schmid et al (2008). 
17 Medicaid is a health insurance program available only to certain low-income individuals and families 
who fit into an eligibility group that is recognized by federal and state law.  There were about 82 million 
Medicaid cardiovascular drug prescriptions in 2004. 
18 Medicare is a health insurance program for people age 65 or older, people under age 65 with certain 
disabilities, and people of all ages with End-Stage Renal Disease (permanent kidney failure requiring 
dialysis or a kidney transplant).  There were about 4 million Medicare major cardiovascular procedures 
performed in 2004.  Major cardiovascular surgical procedures are procedures with Berenson-Eggers Type 
of Service (BETOS) codes P2A through P2F, i.e CABG, aneurysm repair, thromboendarterectomy, 
coronary angioplasty (PTCA), pacemaker insertion, and other major cardiovascular procedures.   See 
http://www.cms.hhs.gov/hcpcsreleasecodesets/20_betos.asp.    11
procedure codes established by the American 
Medical Association after 1990 
 
The data used to construct these measures were obtained from a number of sources.
19  As 
discussed in Lichtenberg (2007b), the surgery innovation measures are probably less 
reliable than the drug innovation measures, because FDA approval of a drug is a more 
meaningful indicator than AMA establishment of a new surgical procedure code.  In 
particular, some procedures with “new” procedure codes may be just relabeled or 
reclassified old procedures, rather than true innovations. 
The following table shows the correlations across states (N = 50) between the 
pharmaceutical and surgical innovation measures, both unweighted and weighted by the 
number of prescriptions (n_rx) or the number of major surgical procedures (n_proc): 
   unweighted  weight=n_rx  weight=n_proc
corr(rx_post1990, surg_post1990)  -0.129  -0.213  -0.180 
p-value 0.378  0.142  0.217 
           
corr(rx_post1995, surg_post1995)  -0.229  -0.473  -0.257 
p-value 0.113  0.001  0.075 
All six correlation coefficients are negative, and one is highly significant.  This suggests 
that, within the U.S., pharmaceutical and non-pharmaceutical cardiovascular disease 
innovation may be substitutes rather than complements.  Therefore, failure to control 
adequately for non-pharmaceutical cardiovascular disease innovation is more likely to 
bias estimates of β towards zero than away from zero.   
                                                 
19 State-level data on Medicaid cardiovascular drug prescriptions were obtained from Medicaid State Drug Utilization 
Files (http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/List.asp).  Data on FDA approval dates were 
obtained from the Drugs@FDA database (http://www.fda.gov/cder/drugsatfda/datafiles/default.htm).  State-level data 
on Medicare major cardiovascular surgical procedures were obtained from the Physician/Supplier Procedure Summary 
Master File 
(http://www.cms.hhs.gov/NonIdentifiableDataFiles/06_PhysicianSupplierProcedureSummaryMasterFile.asp).   Data on 
the dates at which procedure codes were established by the American Medical Association were obtained from the 
AMA’s Current Procedural Terminology Assistant Archives (https://catalog.ama-
assn.org/Catalog/product/product_detail.jsp?childName=&parentCategoryName=&parentCategory=&productId=prod7
80015&categoryName=&prodId=&start=&parentId=).   12
II.  Data sources and descriptive statistics 
 
Data on cardiovascular drug use (number of standard units), by pharmaceutical 
subclass, active ingredient, country, and year, were provided by IMS Health.  There are 
over 1100 ingredients in 29 subclasses in ATC C.  About 1.5 trillion standard units were 
sold in all classes combined in the 21 countries during 1995-2005.  Table 1 shows 
illustrative data, by ingredient, for one subclass (C10A cholesterol & triglyceride 
regulators) in one country (the U.S.) in one year (2005). 
The 'launch date' is the date when a product was first made available to the market 
(although there are circumstances when the launch date is considered to be the date when 
the first pack was included in the IMS data, or first accrued sales). The world launch date 
of some ingredients is unknown.  Many of these ingredients are naturally occurring.  The 
fraction of standard units with missing launch dates declined from 12% in 1995 to 6% in 
2005. 
Two features of the data are worth noting.  First, a given ingredient may appear in 
several subclasses.  Second, a given product may contain several ingredients.  To avoid 
giving too much weight to combination products when calculating mean vintage, we used 
a two-step procedure to calculate mean vintage.  First, we used the ingredient-level data 
to calculate mean vintage in each subclass, country, and year.  Then, we used the 
subclass-level data to calculate mean vintage in each country and year, weighting by the 
number of sub-class SUs (not the sum of the number of ingredient SUs within the sub-
class). 
The mean vintage of cardiovascular drugs varies considerably across countries.  
Figure 1 shows post-1995 SUs as a percentage of total SUs in 2004, by country.  In the 
top 5 countries, at least 13% of SUs were post-1995 SUs.  In the bottom 4, only 1% of 
SUs were post-1995 SUs.  It is not surprising that these are the emerging economies of 
Eastern Europe.  However there are also sharp differences in cardiovascular drug vintage 
between countries that are otherwise similar.  Switzerland’s post-1995 share (11%) is 
more than twice as high as Austria’s (5%).  Australia’s post-1995 share (20%) is four 
times as large as New Zealand’s (5%).  Table 2 further documents these differences by   13
showing the top 10 (ranked by number of SUs) cardiovascular drugs in these four 
countries in 2005.  Descriptive statistics for all variables are shown in Table 3. 
 
III.  Empirical results 
 
  Estimates of eq. (1) based on the first measure of cardiovascular drug vintage 
(rx_post1995%, the fraction of standard units whose active ingredients were launched 
after 1995) are shown in Table 4.  Estimates based on the second measure of 
cardiovascular drug vintage (rx_post1990%) are shown in Table 5.   
First we will discuss the estimates shown in Table 4.  In model 1, the dependent 
variable is the log of the number of cardiovascular disease hospital discharges per 
100,000 population.  The rx_post1995% coefficient is negative and highly significant (p-
value < .0001).  This signifies that countries with larger increases in the share of 
cardiovascular drug SUs that were post-1995 SUs had smaller increases in the 
cardiovascular disease hospital discharge rate, ceteris paribus.   
The coefficient on per capita cardiovascular drug use is not significantly different 
from zero.  As noted above, the net effect of an increase in per capita consumption of 
cardiovascular drugs on cardiovascular hospitalization is theoretically ambiguous.   
  Coefficients on four of the covariates are statistically significant (p-value < .05).  
The coefficient on age_ge_65% is positive and significant, as one would expect: 
cardiovascular hospital utilization increases when the fraction of the population that is 
elderly rises.  The coefficient on the log of the number of CT scanners per million 
population is also positive and significant.  This is consistent with the view that some 
diagnostic innovations may increase utilization of hospital care.
20  Increased consumption 
of tobacco is also positively associated with cardiovascular hospital utilization, but 
calorie consumption is inversely related to cardiovascular hospital utilization. 
  The dependent variable in model 2 is the log of average length of cardiovascular 
disease hospital stays.  Once again, the rx_post1995% coefficient is negative and 
significant (p-value = .03).  This implies that using newer drugs has reduced average 
                                                 
20 The Kaiser Family Foundation (2007), citing Rettig (1994), says that “advances in medical technology 
have contributed to rising overall U.S. health care spending.”     14
length of stay.  The coefficient on GDP is also negative and significant: average length of 
stay has declined faster in countries with higher growth in per capita GDP.  Length of 
stay is positively correlated with calorie and alcohol consumption, but negatively 
correlated with tobacco consumption.  The fact that the coefficient on edu_max% is 
positive and significant suggests that ALOS has declined more slowly in countries where 
the fraction of the population that is highly educated has increased the most.
21  However 
the implied effect of education on ALOS is quite small: if the entire population shifted 
from the low education to the maximum education category, ALOS would increase by 
less than 4%. 
The dependent variable in model 3 is the log of the number of hospital days in 
which the principal diagnosis was cardiovascular disease per 100,000 population.  The 
coefficients in model 3 are equal to the sums of the coefficients in models 1 and 2.  Once 
again, the rx_post1995% coefficient is negative and highly significant.  The only other 
variables whose coefficients are significant are ln(ct_scan), age_ge_65%, and 
edu_max%. 
The dependent variable in model 4 is the (age-standardized) number of deaths 
caused by diseases of the circulatory system per 100,000 population.  The drug vintage 
coefficient is also negative and highly significant (p-value = .0059) in this model.  This 
implies that using newer cardiovascular drugs has reduced the age-adjusted 
cardiovascular disease mortality rate.   The coefficient on per capita drug consumption is 
positive and significant.  Presumably this is because increased per capita cardiovascular 
drug consumption is indicative of increased cardiovascular disease prevalence.  The 
coefficient on ln(calories) is positive and significant at the 10% level.  This may reflect 
the effect of obesity on cardiovascular mortality.  The education coefficients are 
significant, but the implied effect of changes in the educational attainment distribution on 
cardiovascular mortality is quite small. 
The dependent variable in model 5 is the log of the number of potential years of 
life lost due to cardiovascular disease before age 70 per 100,000 population.  This 
measure gives a great deal of weight to deaths that occur well before the age of 70, and 
                                                 
21 Lichtenberg (2007c) finds a positive association across U.S. states between per capita hospital 
expenditure growth and growth in educational attainment during the period 1991-2004, controlling for a 
number of other factors.   15
no weight to deaths that occur after the age of 70.  This is the only model in which the 
drug vintage coefficient is not statistically significant.   
To summarize, estimates based on one measure of cardiovascular drug vintage—
the fraction of standard units whose active ingredients were launched after 1995—are 
consistent with the hypothesis that use of newer cardiovascular drugs has reduced the 
number of cardiovascular hospital discharges, average length of stay, and hospital days.  
The estimates also indicate that use of newer cardiovascular drugs has reduced the age-
adjusted cardiovascular mortality rate, but not the number of potential years of life lost 
due to cardiovascular disease before age 70 per 100,000 population.  Table 5 shows that 
similar results are obtained when we use an alternative measure of cardiovascular drug 
vintage—the fraction of standard units whose active ingredients were launched after 
1990. 
 
IV.  Implications of the estimates 
 
  During the period 1995-2004, the mean vintage of cardiovascular drugs increased: 
the mean fraction of post-1995 drugs increased from 0.0% to 9.6%, and the mean fraction 
of post-1990 drugs increased from 1.4% to 14.7%.  The vintage coefficient estimates 
presented in Tables 4 and 5 imply that this increase in vintage reduced the cardiovascular 
hospitalization rate, length of stay, and age-adjusted mortality.  In other words, if drug 
vintage had not increased during 1995-2004, the number of hospital discharges, hospital 
days, and deaths would have been higher in 2004.  The magnitudes of the implied 
increases are shown in Table 6.  The two vintage measures yield similar estimates of the 
increase in the number of discharges in 2004 had there been no increase in vintage after 
1995.  The mean of these estimates is 51%.  The mean estimate of the increase in average 
length of stay is 12%, and of the increase in hospital days is 70%. 
We estimate that per capita expenditure for cardiovascular hospital stays would 
have been $89 higher in 2004 had drug vintage not increased during 1995-2004.  This is 
how we derived this estimate.  In 2004, mean per capita expenditure on hospital care for 
all diagnostic categories in OECD countries was $926.  We estimate that cardiovascular   16
hospitalizations account for about 14% of total hospital expenditure.
22  Hence mean per 
capita expenditure on cardiovascular hospital care in OECD countries was $128 (= 14% * 
$926).  The vintage coefficient estimates imply that, absent the 1995-2004 increase in 
drug vintage, there would have been 70% more cardiovascular hospital days in 2004.  
Hence per capita expenditure for cardiovascular hospital stays would have been $89 (= 
70% * $128) higher had drug vintage not increased. 
It is reasonable to expect that per capita expenditure on cardiovascular drugs 
would have been lower in 2004 had drug vintage not increased during 1995-2004.  The 
OECD Health Data 2006 database contains some information on sales of pharmaceutical 
products by selected Anatomic Therapeutic Chemical (ATC) groups, based on retail 
prices.  In particular, it contains information about per capita sales of cardiovascular 
system drugs, in U.S. PPP dollars.  To assess the effect of cardiovascular drug vintage on 
per capita expenditure on cardiovascular drugs, we estimated the following model: 
 
ln(cardio_rx_expendit) = π rx_vintit + γ ln(n_cv_suit) + αi + δt + εit    
 
Estimates of π based on the two different drug vintage measures are shown in Table 7. 
Both estimates are positive and significant, as one would expect: countries with larger 
increases in the share of SUs that were for post-1995 or post-1990 drugs had larger 
increases in per capita drug expenditure, conditional on growth in the number of SUs per 
capita.   
To be conservative, we will use the larger (more negative) estimate of the 
reduction in 2004 per capita drug expenditure that would have occurred had drug vintage 
not increased after 1995: 25.1%.  Mean per capita expenditure on all prescription drugs in 
OECD countries was $477 in 2004.  Cardiovascular drug expenditure accounted for 
about 20% of total drug expenditure, so per capita expenditure on cardiovascular drugs in 
OECD countries was $95 (= 20% * $477) in 2004.  The more conservative estimate 
implies that per capita cardiovascular drug expenditure would have been $24 (= 25.1% * 
$95) lower in 2004 had drug vintage not increased after 1995.  Our estimate of the 
increase in per capita expenditure for cardiovascular hospital stays that would occurred 
                                                 
22 Cardiovascular hospitalizations account for about 14% of total hospital bed days.    17
had drug vintage not increased ($89) is about 3.7 times as large as our estimate of the 
reduction in per capita expenditure for cardiovascular drugs that would have occurred 
($24).   
V.  Summary 
 
This study has examined the effect of changes in the vintage distribution of 
cardiovascular system drugs on hospitalization and mortality due to cardiovascular 
disease using longitudinal country-level data on 20 OECD countries during the period 
1995-2003.   
Countries with larger increases in the share of cardiovascular drug SUs that were 
post-1995 SUs had smaller increases in the cardiovascular disease hospital discharge rate, 
controlling for the quantity of cardiovascular medications consumed per person, the use 
of other medical innovations (CT scanners & MRI units), consumption of calories, 
tobacco, and alcohol, and demographic variables (population size & age structure, 
income, and educational attainment).  The estimates also indicate that use of newer 
cardiovascular drugs has reduced average length of stay and the age-adjusted 
cardiovascular mortality rate, but not the number of potential years of life lost due to 
cardiovascular disease before age 70 per 100,000 population. 
The estimates indicate that if drug vintage had not increased during 1995-2004, 
hospitalization and mortality would have been higher in 2004.  We estimate that per 
capita expenditure on cardiovascular hospital stays would have been 70% ($89) higher in 
2004 had drug vintage not increased during 1995-2004.  Per capita expenditure on 
cardiovascular drugs would have been lower in 2004 had drug vintage not increased 
during 1995-2004.  But our estimate of the increase in expenditure on cardiovascular 
hospital stays is about 3.7 times as large as our estimate of the reduction in per capita 
expenditure for cardiovascular drugs that would have occurred ($24).   
  Although our data on hospital use and especially on drug utilization were quite 
complete and reliable, data on cardiovascular risk factors were less complete.  We can 
think of little reason to expect these risk factors to be correlated with drug vintage, 
conditional on income, education, and average rate of drug utilization (which we control   18
for).  Nevertheless, obtaining better information on these risk factors would certainly be 
desirable.   19
References 
 
Aldonas, Grant D. (2005), “Pharmaceutical Price Controls in OECD Countries, 
Implications for American Consumers, Pricing, Research and Development, and 
Innovation,” Testimony of Under Secretary for International Trade, U.S. Department of 
Commerce Before the Committee on Health, Education, Labor and Pensions, U.S. 
Senate, Washington, D.C., February 17, 
http://www.ita.doc.gov/media/Speeches/0205/aldonas_021705.html, accessed 10 January 
2008. 
 
Bahk, Byong-Hyong and Michael Gort (1993), “Decomposing Learning by Doing in 
New Plants,” Journal of Political Economy, 101, 561-583. 
 
Boucekkine, Raouf, David de la Croix, and Omar Licandro, “Vintage Capital,” 
Department of Economics, European University Institute, Eco No. 2006/08 
http://cadmus.iue.it/dspace/bitstream/1814/4346/1/ECO2006-8.pdf, accessed 10 January 
2008. 
 
Cannon, Christopher P., et al (2004), “Intensive versus Moderate Lipid Lowering with 
Statins after Acute Coronary Syndromes,” New England Journal of Medicine 350 (15), 
1495-1504, April 8. 
 
Harrigan CJ. Appelbaum E. Maron BJ. Buros JL. Gibson CM. Lesser JR. Udelson JE. 
Manning WJ. Maron MS. Significance of papillary muscle abnormalities identified by 
cardiovascular magnetic resonance in hypertrophic cardiomyopathy.  American Journal 
of Cardiology. 101(5):668-73, 2008 Mar 1. 
 
Hulten, Charles R. (1992), “Growth accounting when technical change is embodied in 
capital,” The American Economic Review, Vol. 82, No. 4. (Sep., 1992), pp. 964-980. 
 
IMS Health (2006), IMS Retail Drug Monitor, Tracking 13 Key Global Pharma Markets, 
12 months to December 2006, 
http://www.imshealth.com/ims/portal/front/indexC/0,2773,6599_41382715_0,00.html, 
accessed 10 January 2008. 
 
Kaiser Family Foundation (2007), “How Changes in Medical Technology Affect Health 
Care Costs,” March, http://www.kff.org/insurance/snapshot/chcm030807oth.cfm#front5, 
accessed 10 January 2008. 
 
Lichtenberg, Frank (2001), “Are the Benefits of Newer Drugs Worth Their Cost? 
Evidence from the 1996 MEPS,” Health Affairs 20(5), September/October 2001, 241-51. 
 
Lichtenberg, Frank (2006a).  “The effect of using newer drugs on admissions of elderly 
Americans to hospitals and nursing homes: state-level evidence from 1997-2003,” 
Pharmacoeconomics 24 Suppl 3:5-25. 
   20
Lichtenberg, Frank (2006b).  "On 'New Cardiovascular Drugs: Pattern of Use and 
Association with Non-Drug Health Expenditures'”. Inquiry. 2006 Spring; 43(1): 80-2. 
 
Lichtenberg, Frank (2006c), “The impact of increased utilization of HIV drugs on 
longevity and medical expenditure: an assessment based on aggregate U.S. time-series 
data,” Expert Review of Pharmacoeconomics and Outcomes Research, Volume 
6, Number 4, August, 425-436. 
 
Lichtenberg, Frank (2007a), “The impact of new drugs on US longevity and medical 
expenditure, 1990-2003: Evidence from Longitudinal, Disease-Level data,” American 
Economic Review 97 (2), May, 438-443. 
Lichtenberg, Frank (2007b), "Pharmaceutical Innovation and U.S. Cancer Survival, 
1992-2003: Evidence from Linked SEER-MEDSTAT Data," Forum for Health 
Economics & Policy: Vol. 10: Iss. 1 (Frontiers in Health Policy Research), Article 1.  
http://www.bepress.com/fhep/10/1/1  
Lichtenberg, Frank (2007c), “Why Has Longevity Increased More in Some States than in 
Others? The Role of Medical Innovation and Other Factors,” Manhattan Institute for 
Policy Research, Medical Progress Report No. 4,  July, http://www.manhattan-
institute.org/html/mpr_04.htm, accessed 10 January 2008. 
 
Miller GE, Moeller JF, Stafford RS (2005). ”New cardiovascular drugs: patterns of use 
and association with non-drug health expenditures.”  Inquiry. 2005-2006 Winter; 42(4): 
397-412. 
 
Popovic JR, and MJ Hall (2001), “1999 National Hospital Discharge Survey. Advance 
data from vital and health statistics,” no 319. Hyattsville, Maryland: National Center for 
Health Statistics.  http://www.cdc.gov/nchs/data/ad/ad319.pdf, accessed 10 January 2008. 
 
Rettig, Richard A. (1994), “Medical Innovation Duels Cost Containment,” Health Affairs 
(Summer): 15. 
 
Sakellaris, Plutarchos and Dan Wilson (2004), “Quantifying Embodied Technological 
Change,” Review of Economic Dynamics 7(1), pp. 1-26. 
 
Schmid M. Achenbach S. Ropers D. Komatsu S. Ropers U. Daniel WG. Pflederer T. 
Assessment of changes in non-calcified atherosclerotic plaque volume in the left main 
and left anterior descending coronary arteries over time by 64-slice computed 
tomography. American Journal of Cardiology. 101(5):579-84, 2008 Mar 1. 
 
Weisfeldt, ML, and SJ Zieman (2007), “Advances in the prevention and treatment of 
cardiovascular disease,” Health Affairs 26(1), Jan-Feb, 25-37. 
   21
Zhou Z, E Rahme, and L Pilote (2006). "Are statins created equal? Evidence from 
randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease 






     C10A  cholesterol & triglyceride regulator   8,464,846
       ATORVASTATIN 1/1997 3,144,330
       SIMVASTATIN 6/1988 1,555,881
       GEMFIBROZIL 2/1982 548,762
       EZETIMIBE 11/2002 539,047
       LOVASTATIN 9/1987 525,054
       PRAVASTATIN 10/1989 493,161
       FENOFIBRATE 4/1975 428,381
       NICOTINIC ACID   366,023
       ROSUVASTATIN 2/2003 343,580
       COLESEVELAM 9/2000 193,975
       FLUVASTATIN 2/1994 182,766
       COLESTYRAMINE 4/1967 96,573
       COLESTIPOL 3/1977 47,313
       ACETYLSALICYLIC ACID 1/1910 213
       ALLIUM SATIVUM 1/1919 0
       ASCORBIC ACID   0
       CERIVASTATIN 4/1997 0
       CLOFIBRATE   0
       DEXTROTHYROXINE   0
       GLYCINE MAX   0
       LECITHIN   0
       NICOTINAMIDE   0
       PROBUCOL 2/1977 0
       PYRIDOXINE 1/1908 0
       RIBOFLAVIN   0
       THIAMINE   0
       VITAMIN E   0
Table 1
Number of standard units of cholesterol & triglyceride regulator agents sold in the U.S. 
in 2005, by active ingredientFigure 1





























































































































1959 6% C9B ACE INHIBITORS 
COMBINAT
HEPARIN 1910 3% C5B VARICOSE 
THERAPY,TOPICAL
METOPROLOL 1975 3% C7A B-BLOCKING 
AGENTS,PLAIN
ATORVASTATIN 1997 2% C10A 
CHOLEST&TRIGLY.R
EGULATOR
AMLODIPINE 1990 3% C8A CALCIUM 
ANTAGONIST PLAIN








1959 2% C9B ACE 
INHIBITORS 
COMBINAT
FUROSEMIDE 1964 3% C3A DIURETICS
TORASEMIDE 1992 2% C3A DIURETICS BISOPROLOL 1986 3% C7A B-BLOCKING 
AGENTS,PLAIN
AMLODIPINE 1990 2% C8A CALCIUM 
ANTAGONIST PLAIN
GINKGO BILOBA 1965 3% C4A CEREBR/PERIPH 
VASOTHERAP
ATENOLOL 1976 2% C7A B-BLOCKING 
AGENTS,PLAIN
SIMVASTATIN 1988 3% C10A 
CHOLEST&TRIGLY.RE
GULATOR
SIMVASTATIN 1988 2% C10A 
CHOLEST&TRIGLY.R
EGULATOR
HEPARIN 1910 3% C5B VARICOSE 
THERAPY,TOPICAL
Table 2
Top 10 (ranked by no. of standard units) cardiovascular drugs in 4 countries in 2005
SWITZERLAND (N=1,903,135) AUSTRIA (N=1,890,382)
AUSTRALIA (N=2,997,258) NEW ZEALAND (N=620,001)Variable MEAN STD. DEV. MIN MAX
number of hospital discharges in which the principal 
diagnosis was cardiovascular disease per 100,000 
population
2330 963 478 4710
number of hospital days in which the principal diagnosis 
was cardiovascular disease per 100,000 population
23701 14935 4646 67314
average length of stay in hospital discharges in which the 
principal diagnosis was cardiovascular disease 
9.708 2.949 4.7 17.3
age-standardized number of deaths caused by diseases of 
the circulatory system per 100,000 population 
280 115 123 562
potential years of life lost due to diseases of the circulatory 
system before age 70 per 100,000 population
743.84 361.8 333 1988
the number of standard units of cardiovascular drugs per 
person
0.143 0.062 0.005 0.279
fraction of standard units whose active ingredients were 
launched after 1995
4.2% 4.7% 0.0% 21.8%
fraction of standard units whose active ingredients were 
launched after 1990
7.4% 6.2% 0.0% 24.9%
number of computed tomography scanners per million 
population
16.281 12.588 3.5 92.6
number of magnetic resonance imaging units per million 
population
6.752 6.058 0.6 40.1
population (in thousands) 37,658 55,552 267 296,972
fraction of the population age 65 and over 13.9% 3.2% 5.0% 20.0%
per capita GDP (in PPP US dollars) $22,866 $8,360 $5,558 $48,162
average number of calories consumed per person per day
3334 253 2768 3817
per capita expenditure on tobacco (in PPP US dollars) $327 $346 $26 $2,662
per capita expenditure on alcohol (in PPP US dollars) $279 $138 $43 $788
fraction of the population with education at or below the 
lower secondary level (ISCED 0/1/2) 29.8% 17.2% 10.7% 79.0%
fraction of the population with education at the upper 
secondary or post-secondary, non-tertiary level (ISCED 3/4) 47.4% 16.3% 11.9% 76.7%
fraction of the population with education at the tertiary level 




Parameter estimate t-value prob>t estimate t-value prob>t estimate t-value prob>t estimate t-value prob>t estimate t-value prob>t
rx_post1995% -4.013 -5.51 <.0001 -0.858 -2.30 0.0271 -4.870 -5.83 <.0001 -0.846 -2.88 0.0059 0.333 0.61 0.5447
ln(n_cv_su) 0.006 0.47 0.6418 0.012 1.78 0.0831 0.018 1.20 0.2363 0.014 2.12 0.0391 0.021 1.74 0.0886
ln(ct_scan) 0.289 2.63 0.0123 0.058 1.03 0.3084 0.347 2.75 0.009 -0.029 -0.69 0.4911 -0.041 -0.53 0.5994
ln(mri) -0.043 -0.76 0.4545 0.046 1.58 0.1224 0.003 0.05 0.9629 0.007 0.22 0.8235 -0.068 -1.24 0.2192
ln(calories) -1.324 -2.48 0.0178 0.754 2.75 0.009 -0.571 -0.93 0.3583 0.464 1.81 0.0764 1.239 2.60 0.0122
ln(tobacco) 0.463 2.94 0.0055 -0.168 -2.09 0.0434 0.295 1.63 0.1111 0.052 0.70 0.4888 -0.133 -0.97 0.3378
ln(alcohol) -0.233 -1.03 0.3094 0.539 4.65 <.0001 0.306 1.18 0.2448 -0.061 -0.60 0.5516 -0.195 -1.04 0.3027
ln(population) 1.936 1.37 0.1781 0.476 0.66 0.5141 2.412 1.49 0.1444 -0.030 -0.05 0.9632 0.326 0.27 0.7877
age_ge_65% 0.080 2.58 0.0139 -0.007 -0.41 0.6845 0.073 2.06 0.0458
ln(gdp) 0.160 0.42 0.6792 -0.518 -2.63 0.0123 -0.357 -0.81 0.4232 -0.072 -0.40 0.6898 0.267 0.80 0.4259
edu_low% -0.023 -1.93 0.0603 0.004 0.63 0.5323 -0.019 -1.40 0.168 0.015 2.69 0.0098 0.036 3.59 0.0008
edu_mid% -0.016 -1.01 0.321 0.011 1.35 0.1857 -0.005 -0.27 0.7851 0.015 2.14 0.0371 0.035 2.70 0.0096
edu_max% 0.020 0.82 0.4176 0.039 3.12 0.0034 0.058 2.11 0.0416 0.022 2.54 0.0142 0.034 2.14 0.0371
year 1995 0.182 1.27 0.211 0.290 3.94 0.0003 0.472 2.87 0.0066 0.207 3.56 0.0008 0.301 2.79 0.0074
year 1996 0.100 0.74 0.4663 0.209 3.02 0.0045 0.309 1.99 0.0539 0.162 3.18 0.0025 0.268 2.83 0.0067
year 1997 0.082 0.73 0.4688 0.167 2.93 0.0056 0.249 1.95 0.0587 0.129 2.79 0.0074 0.245 2.86 0.0062
year 1998 0.101 1.09 0.2843 0.126 2.65 0.0115 0.227 2.13 0.0395 0.117 2.94 0.0049 0.217 2.94 0.005
year 1999 0.102 1.39 0.1737 0.106 2.82 0.0076 0.208 2.47 0.0182 0.098 3.01 0.0041 0.185 3.08 0.0034
year 2000 0.095 1.64 0.1091 0.088 2.98 0.005 0.183 2.76 0.0088 0.057 2.20 0.0323 0.136 2.86 0.0063
year 2001 0.065 1.71 0.0959 0.068 3.46 0.0013 0.133 3.03 0.0043 0.028 1.52 0.1352 0.090 2.62 0.0116
year 2002 0.037 1.40 0.1702 0.050 3.71 0.0006 0.087 2.88 0.0065 0.019 1.46 0.1509 0.058 2.34 0.0231
year 2003 0.000 . . 0.000 . . 0.000 . . 0.000 . . 0.000 . .
R
2 0.993 0.997 0.996 0.997 0.990
Degrees of 
freedom
Model 36 36 36 33 33
Error 39 39 39 49 49
Corrected Total 75 75 75 82 82
Note: all models include country fixed effects.
5
Estimates of eq. (1): ln Yit = β rx_post1995%it + γ Zit + αi + δt + εit
Table 4
13 24
ln(n_discharges) ln(n_days) ln(alos) ln(pyll) ln(n_deaths)Model
Dep. Var.
Parameter estimate t-value prob>t estimate t-value prob>t estimate t-value prob>t estimate t-value prob>t estimate t-value prob>t
rx_post1990% -3.270 -3.01 0.0046 -1.087 -2.35 0.0239 -4.357 -3.52 0.0011 -0.915 -2.67 0.0103 -0.296 -0.47 0.6406
ln(n_cv_su) 0.011 0.74 0.465 0.013 1.98 0.055 0.024 1.39 0.1729 0.015 2.32 0.0245 0.019 1.6 0.1169
ln(ct_scan) 0.205 1.58 0.1232 0.051 0.92 0.3629 0.256 1.73 0.0917 -0.028 -0.67 0.5087 -0.058 -0.74 0.4627
ln(mri) -0.023 -0.34 0.7383 0.052 1.78 0.0828 0.029 0.37 0.7134 0.023 0.77 0.4426 -0.066 -1.18 0.2439
ln(calories) -1.729 -2.68 0.0106 0.644 2.35 0.0239 -1.085 -1.48 0.1469 0.374 1.43 0.1584 1.218 2.54 0.0144
ln(tobacco) 0.536 2.77 0.0084 -0.139 -1.69 0.0989 0.397 1.81 0.0785 0.082 1.11 0.2727 -0.156 -1.15 0.2541
ln(alcohol) -0.415 -1.54 0.1318 0.497 4.33 0.0001 0.082 0.27 0.7915 -0.093 -0.91 0.3663 -0.187 -1 0.3232
ln(population) 1.085 0.64 0.5289 0.521 0.72 0.4774 1.606 0.83 0.4134 -0.187 -0.29 0.7697 1.045 0.89 0.376
age_ge_65% 0.097 2.59 0.0133 -0.002 -0.11 0.9099 0.095 2.24 0.0311
ln(gdp) 0.594 1.3 0.2018 -0.413 -2.12 0.0405 0.182 0.35 0.7291 -0.021 -0.12 0.9081 0.290 0.86 0.3922
edu_low% -0.031 -2.16 0.0369 0.002 0.31 0.7583 -0.029 -1.78 0.0823 0.012 2.14 0.0378 0.037 3.71 0.0005
edu_mid% -0.020 -1.06 0.2971 0.010 1.2 0.2363 -0.010 -0.48 0.6345 0.012 1.71 0.0933 0.033 2.51 0.0153
edu_max% 0.007 0.24 0.8082 0.039 3.16 0.0031 0.046 1.4 0.1707 0.023 2.68 0.0099 0.036 2.23 0.0306
year 1995 0.208 1.2 0.2375 0.284 3.85 0.0004 0.491 2.49 0.017 0.214 3.67 0.0006 0.262 2.44 0.0182
year 1996 0.125 0.77 0.4487 0.202 2.89 0.0062 0.327 1.75 0.0873 0.168 3.28 0.0019 0.227 2.42 0.0195
year 1997 0.128 0.95 0.347 0.163 2.85 0.0069 0.292 1.9 0.0645 0.134 2.88 0.0059 0.204 2.38 0.0214
year 1998 0.149 1.34 0.1893 0.125 2.63 0.012 0.275 2.16 0.0371 0.123 3.12 0.003 0.180 2.47 0.017
year 1999 0.133 1.5 0.141 0.105 2.8 0.008 0.238 2.37 0.023 0.101 3.08 0.0033 0.158 2.62 0.0116
year 2000 0.110 1.59 0.1196 0.090 3.04 0.0042 0.200 2.54 0.0153 0.060 2.35 0.0229 0.119 2.51 0.0153
year 2001 0.070 1.52 0.1361 0.069 3.52 0.0011 0.138 2.65 0.0115 0.030 1.58 0.1195 0.080 2.31 0.025
year 2002 0.045 1.43 0.1618 0.052 3.86 0.0004 0.097 2.7 0.0103 0.021 1.56 0.1243 0.055 2.21 0.0314
year 2003 0.000 . . 0.000 . . 0.000 . . 0.000 . . 0.000 . .
R
2 0.990 0.997 0.994 0.997 0.990
Degrees of 
freedom
Model 36 36 36 33 33
Error 39 39 39 49 49
Corrected Total 75 75 75 82 82
Note: all models include country fixed effects.
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Table 5
Estimates of eq. (1): ln Yit = β rx_post1990%it + γ Zit + αi + δt + εit
13 24
ln(n_discharges) ln(n_days) ln(alos) ln(pyll) ln(n_deaths)vintage measure 
(rx_vint)
1995-2004 change in 
vintage measure 
(rx_vint2004 - rx_vint1995)
n_discharges alos n_days n_deaths
rx_post1995% 10% 47% 9% 60% 9%
rx_post1990% 13% 55% 16% 79% 13%
average 51% 12% 70% 11%
Table 6
% increase in dependent variable in 2004 if no 1995-2004 change in drug vintage
 % increase in dependent variable in 2004 if no 
1995-2004 change in drug vintage
  [exp(-β (rx_vint2004 - rx_vint1995))] - 1vintage measure 
(rx_vint) π t-stat p-value
[exp(-π (rx_vint2004 - rx_vint1995))]-1
rx_post1995% 2.70 2.99 0.004 -22.90%
rx_post1990% 2.16 2.34 0.022 -25.10%
Estimates of π based on the two different drug vintage measures
ln(cardio_rx_expendit) = π rx_vintit + γ ln(n_cv_suit) + αi + δt + εit
Table 7
Estimates of the effect of cardiovascular drug vintage on per capita expenditure on 
cardiovascular drugs